February 17th 2025
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.
February 12th 2025
Bringing New Solutions into View for Cell and Gene Therapies: Masahide Goto, President, AIRM
January 31st 2022Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options.
Shining a Light on Rare Disease: Evidence Challenges and Solutions
January 19th 2022Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
2022 Pipeline Report: Capitalizing on Opportunity
December 9th 2021Our annual report takes a look at pharma’s current investment in drug development, which this year demonstrates a focus on five important therapeutic areas of interest—Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids.
A New Level of Immunology: Sanjay Shukla, aTyr Pharma
September 30th 2021aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.
Broadening the Scope of Small Molecules: Ventus Therapeutics
July 13th 2021Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.
Tuning and Tracking CAR-T Cells for Safer and More Effective Treatment for Solid Tumors
June 23rd 2021With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.
Moving Beyond Traditional Approaches to Alzheimer’s Disease
June 8th 2021The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
Protecting Nerve Cells in the Fight Against Alzheimer’s Disease: Dr. Maria Maccecchini
May 14th 2021Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.